1. Home
  2. KPLT vs PMN Comparison

KPLT vs PMN Comparison

Compare KPLT & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Katapult Holdings Inc.

KPLT

Katapult Holdings Inc.

HOLD

Current Price

$6.94

Market Cap

32.7M

ML Signal

HOLD

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$12.88

Market Cap

34.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPLT
PMN
Founded
2012
2004
Country
United States
Canada
Employees
94
N/A
Industry
Diversified Commercial Services
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7M
34.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
KPLT
PMN
Price
$6.94
$12.88
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$10.00
$42.67
AVG Volume (30 Days)
22.4K
40.5K
Earning Date
03-11-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.62
N/A
Revenue Next Year
$15.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.50
$0.29
52 Week High
$24.15
$27.40

Technical Indicators

Market Signals
Indicator
KPLT
PMN
Relative Strength Index (RSI) 56.04 33.55
Support Level $5.78 $0.41
Resistance Level $7.58 $19.85
Average True Range (ATR) 0.40 2.24
MACD 0.03 -0.99
Stochastic Oscillator 73.48 5.07

Price Performance

Historical Comparison
KPLT
PMN

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: